ANNX | Ticker Profile - Titan Protect

ANNX

Annexon, Inc.

Healthcare · Biotechnology · NMS

$5.29

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$883M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-5.84

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-87.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$11.50

+117% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 8 analysts covering this stock

About Annexon, Inc.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

https://www.annexonbio.com

Country: United States Employees: 93 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.476

Positive but modest risk-adjusted returns

Kelly Fraction

0.0184

Marginal edge — very small allocation suggested

Calmar Ratio

0.085

Drawdown risk outweighs the returns — higher risk profile

Annual Return

6.9%

Historical annualised return based on price data

Max Drawdown

-81.9%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

109

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.22

Moves slightly more than the broader market

52W High

$7.18

26% below the year high

52W Low

$1.85

186% above the year low

Avg Volume

2,550,175

Average daily shares traded — higher means easier to buy and sell

Short Ratio

11.5

Days it would take all short sellers to cover — higher means more crowded

Short % Float

15.8%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.20

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

12.44

Heavy leverage — higher financial risk if revenues decline

Current Ratio

6.35

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

6.26

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

$-107,338,376

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-198,332,992

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$27.00

Target Median

$11.50

Target Low

$7.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go